PubRank

John S Tregoning

Author PubWeight™ 23.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 2005 1.94
2 A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006 1.82
3 Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol 2008 1.76
4 Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur J Immunol 2011 1.53
5 CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010 1.51
6 Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol 2006 1.33
7 Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 2012 1.22
8 Role of CCL5 (RANTES) in viral lung disease. J Virol 2006 1.21
9 Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose. Thorax 2013 1.12
10 Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol 2005 1.12
11 Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells. J Virol 2010 1.09
12 Childhood infections, the developing immune system, and the origins of asthma. J Allergy Clin Immunol 2004 1.05
13 Virally delivered cytokines alter the immune response to future lung infections. J Virol 2007 1.01
14 Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J Virol 2010 0.97
15 Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One 2013 0.95
16 Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine 2011 0.90
17 Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice. PLoS One 2013 0.88
18 Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection. J Virol 2012 0.88
19 Using Plasmids as DNA Vaccines for Infectious Diseases. Microbiol Spectr 2014 0.88
20 Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system. J Virol 2013 0.83